We used data from the NICHD Study of Early Child Care and Youth Development and latent class analysis to model patterns of maternal depressive symptoms from infant age 1 month to the transition to adolescence (age 12), and then examined adolescent adjustment at age 15 as a function of the course and severity of maternal symptoms. We identified five latent classes of symptoms in these 1357 women while also taking into account sociodemographic measures: never depressed; stable subclinical; early-decreasing; moderately elevated; chronic. Women with few symptoms were more likely to be married, better educated, and in better physical health than women with more elevated symptoms. Family size and whether the pregnancy was planned also differentiated among classes. At age 15, adolescents whose mothers were in the chronic, elevated, and stable subclinical latent classes reported more internalizing and externalizing problems and acknowledged engaging in more risky behavior than did children of never-depressed mothers. Latent class differences in self-reported loneliness and dysphoria were also found. Finally, several significant interactions between sex and latent class suggested that girls whose mothers reported elevated symptoms of depression over time experienced more internalizing distress and dysphoric mood relative to their male counterparts. Discussion focuses on adolescent adjustment, especially among offspring whose mothers report stable symptoms of depression across their childhoods. Keywordsmaternal depressive symptoms; latent class analysis; longitudinal study; offspring adjustment; adolescent outcomes A large literature links maternal depression and maternal depressive symptoms to poorer social and emotional outcomes in children across a wide age range from infancy to adolescence (see Goodman & Gotlib, 2002 for reviews). A comprehensive developmentalCorrespondence concerning this article should be addressed to Susan B. Campbell, Department of Psychology, University of Pittsburgh, 210 South Bouquet Street, Pittsburgh, PA 15260 (e-mail: sbcamp@pitt.edu).. Publisher's Disclaimer: The following manuscript is the final accepted manuscript. It has not been subjected to the final copyediting, fact-checking, and proofreading required for formal publication. It is not the definitive, publisher-authenticated version. The American Psychological Association and its Council of Editors disclaim any responsibility or liabilities for errors or omissions of this manuscript version, any version derived from this manuscript by NIH, or other third parties. The published version is available at www.apa.org/journals/abn. NIH Public AccessAuthor Manuscript J Abnorm Psychol. Author manuscript; available in PMC 2010 August 1. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript model proposed to account for these associations by Goodman and Gotlib (1999) highlights several important factors. Along with the biological and genetic risk conferred by a depressed mother, characteristics of the depression it...

Mediational links between parenting styles (authoritative, authoritarian, permissive), impulsiveness (general control), drinking control (specific control), and alcohol use and abuse were tested. A pattern-mixture approach (for modeling non-ignorable missing data) with multiple-group structural equation models with 421 (206 female, 215 male) college students was used. Gender was examined as a potential moderator of parenting styles on control processes related to drinking. Specifically, the parent-child gender match was found to have implications for increased levels of impulsiveness (a significant mediator of parenting effects on drinking control). These findings suggest that a parent with a permissive parenting style who is the same gender as the respondent can directly influence control processes and indirectly influence alcohol use and abuse.

Mediated moderation occurs when the interaction between two variables affects a mediator, which then affects a dependent variable. In this article, we describe the mediated moderation model and evaluate it with a statistical simulation using an adaptation of product-of-coefficients methods to assess mediation. We also demonstrate the use of this method with a substantive example from the adolescent tobacco literature. In the simulation, relative bias (RB) in point estimates and standard errors did not exceed problematic levels of Ϯ10%, although systematic variability in RB was accounted for by parameter size, sample size, and nonzero direct effects. Power to detect mediated moderation effects appears to be severely compromised under one particular combination of conditions: when the component variables that make up the interaction terms are correlated and partial mediated moderation exists. Implications for the estimation of mediated moderation effects in experimental and nonexperimental research are discussed.

We examined heterogeneity in BMI trajectory classes among youth and variables that may be associated with trajectory class membership. We used data from seven rounds (1997–2003) of the 1997 National Longitudinal Survey of Youth (NLSY97), a nationally representative, longitudinal survey of people born between 1980 and 1984 who were living in the United States in 1997. The analyses were based on an accelerated longitudinal design. General growth mixture modeling implemented in Mplus (version 4.1) was used to identify subtypes of youth BMI growth trajectories over time. Four distinct youth BMI trajectories were identified. Class 1 includes youth at high risk for becoming obese by young adulthood (at age 12 and 23, ∼67 and 90%, respectively, are classified as obese, and almost 72% will have had a BMI ≥ 40 at some time during this developmental period). Class 2 includes youth at moderate‐to‐high risk (at age 12 and 23, ∼55 and 68%, respectively, are classified as obese). Class 3 includes youth at low‐to‐moderate risk (i.e., at age 12 and 23, ∼8 and 27%, respectively, are classified as obese). Class 4 includes youth at low risk (few of these youth are obese at any age during this developmental period). These results highlight the importance of considering heterogeneity in BMI growth among youth and early interventions among those most at risk of the adverse health consequences of excess weight.

ObjectiveTo assess the impact of the Women's Health CoOp (WHC) on drug abstinence among vulnerable women having HIV counselling and testing (HCT).DesignRandomised trial conducted with multiple follow-ups.Setting15 communities in Cape Town, South Africa.Participants720 drug-using women aged 18–33, randomised to an intervention (360) or one of two control arms (181 and 179) with 91.9% retained at follow-up.InterventionsThe WHC brief peer-facilitated intervention consisted of four modules (two sessions), 2 h addressing knowledge and skills to reduce drug use, sex risk and violence; and included role-playing and rehearsal, an equal attention nutrition intervention, and an HCT-only control.Primary outcome measuresBiologically confirmed drug abstinence measured at 12-month follow-up, sober at last sex act, condom use with main and casual sex partners, and intimate partner violence.ResultsAt the 12-month endpoint, 26.9% (n=83/309) of the women in the WHC arm were abstinent from drugs, compared with 16.9% (n=27/160) in the Nutrition arm and 20% (n=31/155) in the HCT-only control arm. In the random effects model, this translated to an effect size on the log odds scale with an OR of 1.54 (95% CI 1.07 to 2.22) comparing the WHC arm with the combined control arms. Other 12-month comparison measures between arms were non-significant for sex risk and victimisation outcomes. At 6-month follow-up, women in the WHC arm (65.9%, 197/299) were more likely to be sober at the last sex act (OR1.32 (95% CI 1.02 to 1.84)) than women in the Nutrition arm (54.3%, n=82/152).ConclusionsThis is the first trial among drug-using women in South Africa showing that a brief intervention added to HCT results in greater abstinence from drug use at 12 months and a larger percentage of sexual activity not under the influence of substances.Trial registration numberNCT00729391 ClinicalTrials.gov